HemaFus CBFB-MYH11 Fusion Gene Qualitative Detection Kit (PCR-Fluorescent Probing)

Background

CBFB-MYH11 fusion transcripts formed by Inv(16)(p13q22) or t(16;16)(p13q22) occur not only in the vast majority of typical 4Eo, but also in 10% of M4 without eosinophilic abnormalities, and rarely in M2. Due to different breakpoints of MYH11 gene, over 10 CBFβ-MYH11 fusion transcripts have been reported. Among them, three common spliceosomes (types A, D, and E) have been identified, with type A being the most common, accounting for about 80% of cases. The three most common transcripts together account for about 98% of all types. AML patients with CBFβ-MYH11 are sensitive to chemotherapy, with good prognosis. Therefore, it can be used for efficacy monitoring and minimal residual detection.

Figure 1

Features

Simple operation and less time consumption; reliable results and intuitive interpretation; high sensitivity and sample saving.

Detection Process

In this method, RNA is isolated and purified from leukocytes in peripheral blood or bone marrow samples, and cDNA is obtained by reverse transcription to quantitatively detect the CBFB-MYH11 fusion gene by fluorescence quantitative PCR. The fusion of fusion genes is shown in Figure 2.

Figure 2

Applicable instrument

ABI fluorescence quantitative PCR system (ABI7500, ABI ViiA7)

Ordering Information